サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1309757

感染症の臨床検査分子診断の世界市場：戦略と動向、用途別、技術別、国別予測 - エグゼクティブコンサルタントガイド付き（2023年～2027年）

Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets. Strategies and Trends. Forecasts by Application (Transplant, Respiratory, etc.) by Country. With Market Analysis & Executive Guides. 2023 to 2027
出版日: | 発行: Howe Sound Research | ページ情報: 英文 392 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
感染症の臨床検査分子診断の世界市場：戦略と動向、用途別、技術別、国別予測 - エグゼクティブコンサルタントガイド付き（2023年～2027年）
出版日: 2023年07月18日
発行: Howe Sound Research
ページ情報: 英文 392 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、世界の感染症の臨床検査分子診断市場について調査し、市場の概要とともに、用途別、技術別、製品別、ユーザー別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

第3章 感染症- 病原体ガイド

  • 感染症の病原体- 全体像
  • コロナウイルス
  • HIV-ヒト免疫不全ウイルス（AIDS）
  • HBV-B型肝炎
  • HCV-C型肝炎
  • HPV-ヒトパピローマウイルス
  • インフルエンザ
  • CTGC-クラミジア/淋病
  • 結核
  • MRSA-メチシリン耐性黄色ブドウ球菌
  • VRE-バンコマイシン耐性腸球菌

第4章 業界の概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 計装サプライヤー
    • 薬品・試薬メーカー
    • 病理サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室
    • 監査機関
    • 認証機関
  • 臨床検査市場セグメント
  • 業界構造

第5章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計測、自動化、診断の動向

第6章 臨床検査におけるMDx感染症の最近の動向

第7章 主要企業と競合分析

  • Abbott Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid (Danaher)
  • Hologic
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Qiagen
  • Roche Molecular Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

第8章 世界の感染症の臨床検査分子診断市場

  • 国別の世界市場概要
  • 用途別の世界市場- 概要

第9章 世界の感染症の臨床検査分子診断市場- 用途別

  • 呼吸器系
  • 血液媒介ウイルス
  • 移植
  • 院内感染
  • リプロダクティブヘルス
  • C19シングルプレックス
  • その他

第10章 付録

図表

Table of Tables

  • Table 1 Market Share of Leading Companies
  • Table 2 Viral Pathogens and Families
  • Table 3 Characteristics of Coronavirus Pandemic Infections
  • Table 4 COVID-19 Symptoms
  • Table 5 Classification of HIV Species
  • Table 6 HBV Tests - CMS Codes & Prices
  • Table 7 HCV Tests - CMS Codes & Prices
  • Table 8 HPV Clearance Rates
  • Table 9 HPV Tests - CMS Codes & Prices
  • Table 10 HPV Tests, Technology, Types
  • Table 11 Types of Influenza Tests
  • Table 12 Influenza Tests - CMS Codes & Prices
  • Table 13 FDA Cleared Molecular Assays for Influenza
  • Table 14 FDA Cleared NAAT CTGC Tests
  • Table 15 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 16 Influenza Tests - CMS Codes & Prices
  • Table 17 FDA Approved MDx Tests for Tuberculosis
  • Table 18 Tuberculosis Tests - CMS Codes & Prices
  • Table 19 FDA Approved Tests for MRSA
  • Table 20 MRSA Tests - CMS Codes & Prices
  • Table 21 FDA Approved Tests for VRE
  • Table 22 VRE Tests - CMS Codes & Prices
  • Table 23 FDA Approved Tests for VRE
  • Table 24 VRE Tests - CMS Codes & Prices
  • Table 25 Market Players by Type
  • Table 26 Clinical Laboratory Departments and Segments
  • Table 27 Laboratory Management Focus - Different Approaches
  • Table 28 Key Segmentation Variables Going Forward
  • Table 29 Possible Market Segments of Syndromic Multiplex Market
  • Table 30 Five Factors Driving Growth
  • Table 31 Four Factors Limiting Growth
  • Table 32 Seven Key Diagnostic Laboratory Technology Trends
  • Table 33 - Global Market by Region
  • Table 34 Global Market by Application
  • Table 35 Respiratory by Country
  • Table 36 Blood Borne Virus by Country
  • Table 37 Transplant by Country
  • Table 38 Hospital Acquired Infections by Country
  • Table 39 Reproductive Health by Country
  • Table 40 C19 Singleplex by Country
  • Table 41 Other by Country
  • Table 42 Clinical Lab Fee Schedule
  • Table 43 The Most Common Assays
  • Table 44 Largest Revenue Assays

Table of Figures

  • Figure 1 Market Share of Leading Companies Chart
  • Figure 2 Global Health Care Spending
  • Figure 3 The Lab Test Pie
  • Figure 4 Structure of a Typical Virus
  • Figure 5 Mycobacterium Tuberculosis
  • FIGURE 6 STRUCTURE OF CORONAVIRUSES
  • Figure 7 HIV Virion
  • Figure 8 Diagram of the HIV Replication Cycle
  • Figure 9 The Structure of the HBV Virus
  • Figure 10 Hepatitis B Replication
  • Figure 11 Structure of the HCV Virus
  • Figure 12 HCV Replication Cycle
  • Figure 13 Structure of the Influenza Virion
  • Figure 14 Influenza Replication
  • Figure 15 Scanning Electronmicrograph of Tuberculosis
  • Figure 16 The Road to Diagnostics
  • Figure 17 Percentage of World Population Over 65
  • Figure 18 Chart Infectious Disease Decline
  • Figure 19 Centralized vs. Decentralized Laboratory Service
  • Figure 20 A Highly Multiplexed Syndromic Testing Unit
  • Figure 21 The Real Cost to Sequence the Human Genome
  • Figure 22 The Codevelopment Process
  • Figure 23 Global Market Share Chart
  • Figure 24 Global Market by Application - Base vs. Final
  • Figure 25 Global Market by Application Base Year
  • Figure 26 Global Market by Application End Year
  • Figure 27 Application Share by Year
  • Figure 28 Application Segments Growth
  • Figure 29 Respiratory Growth
  • Figure 30 Blood Borne Virus Diagnostics Growth
  • Figure 31 Transplant Growth
  • Figure 32 Hospital Acquired Infections Growth
  • Figure 33 Reproductive Health Growth
  • Figure 34 C19 Singleplex Growth
  • Figure 35 Other Growth
目次

OVERVIEW:

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report. And find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis
  • 1.2 Market Shares of Leading Companies - Table and Chart

2 Introduction and Market Definition

  • 2.1 Market Definition
    • 2.1.1 Market Size
    • 2.1.2 Currency
    • 2.1.3 Years
  • 2.2 Methodology
    • 2.2.1 Methodology
    • 2.2.2 Sources
    • 2.2.3 Authors
  • 2.3 Perspective: Healthcare and the IVD Industry
    • 2.3.1 Global Healthcare Spending
    • 2.3.2 Spending on Diagnostics
    • 2.3.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Guide to the Pathogens

  • 3.1 Infectious Disease Pathogens - The Big Picture
    • 3.1.1 Viruses
    • 3.1.2 Bacteria
    • 3.1.3 Fungi
    • 3.1.4 Parasites
    • 3.1.5 Prions
    • 3.1.6 Virulence
    • 3.1.7 Transmission
  • 3.2 The Coronavirus
    • 3.2.1 Severe acute respiratory syndrome (SARS)
    • 3.2.2 Middle East respiratory syndrome (MERS)
    • 3.2.3 COVID-19. The SARS CoV 2 Virus.
      • 3.2.3.1 Signs and symptoms
      • 3.2.3.2 Transmission
      • 3.2.3.3 Diagnosis
      • 3.2.3.4 Prevention
      • 3.2.3.5 Management
      • 3.2.3.6 Prognosis
  • 3.4 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.4.1 Virology
      • 3.4.1.1 Classification
      • 3.4.1.2 Structure and genome
      • 3.4.1.3 Tropism
      • 3.4.1.4 Replication cycle
      • 3.4.1.5 Genetic variability
    • 3.4.2 Diagnosis
    • 3.4.3 Testing
      • 3.4.3.1 Antibody tests
      • 3.4.3.2 Point of Care Tests (POCT)
      • 3.4.3.3 Antigen Tests
      • 3.4.3.4 Nucleic acid-based tests (NAT)
      • 3.4.3.5 Other tests used in HIV treatment
  • 3.5 HBV - Hepatitis B
    • 3.5.1 Virology
      • 3.5.1.1 Genome
      • 3.5.1.2 Pathogenesis
      • 3.5.1.3 Hepatitis B virus replication
      • 3.5.1.4 Serotypes and genotypes
    • 3.5.2 Mechanisms
    • 3.5.3 Diagnosis
    • 3.5.4 Market Opportunity Analysis
  • 3.6 HCV - Hepatitis C
    • 3.6.1 Taxonomy
      • 3.6.1.1 Structure
      • 3.6.1.2 Genome
    • 3.6.2 Molecular biology
    • 3.6.3 Replication
    • 3.6.4 Genotypes
      • 3.6.4.1 Clinical importance
    • 3.6.5 Market Opportunity Analysis
  • 3.7 HPV - Human papillomavirus
    • 3.7.1 Virology
      • 3.7.1.1 E6/E7 proteins
      • 3.7.1.2 Role in cancer
      • 3.7.1.3 E2 research
      • 3.7.1.4 Latency period
      • 3.7.1.5 Clearance
    • 3.7.2 Diagnosis
      • 3.7.2.1 Cervical testing
      • 3.7.2.2 Oral testing
      • 3.7.2.3 Testing men
      • 3.7.2.4 Other testing
    • 3.7.3 Market Opportunity Analysis
  • 3.8 Influenza
    • 3.8.1 Virology
      • 3.8.1.1 Types of virus
      • 3.8.1.2 Influenzavirus A
      • 3.8.1.3 Influenzavirus B
      • 3.8.1.4 Influenzavirus C
      • 3.8.1.5 Structure, properties, and subtype nomenclature
      • 3.8.1.6 Replication
    • 3.8.2 Testing
      • 3.8.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.8.3 Market Opportunity Analysis
  • 3.9 CTGC - Chlamydia/Gonorhea
    • 3.9.1 Gonorrhea
      • 3.9.1.1 Diagnosis
      • 3.9.1.2 Screening
    • 3.9.2 Chlamydia
      • 3.9.2.1 Diagnosis
      • 3.9.2.2 Screening
    • 3.9.3 Testing
      • 3.9.3.1 Nucleic acid amplification tests (NAATs).
      • 3.9.3.2 Performance of NAAT Tests
    • 3.9.4 Market Opportunity Analysis
  • 3.10 Tuberculosis
    • 3.10.1 Mycobacteria
    • 3.10.2 Diagnosis
      • 3.10.2.1 Active tuberculosis
      • 3.10.2.2 Latent tuberculosis
    • 3.10.3 Epidemiology
    • 3.10.4 Molecular Diagnostic Tests
    • 3.10.5 Market Opportunity Analysis
  • 3.11 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.11.1 Diagnosis
    • 3.11.2 FDA Approved Molecular Tests
    • 3.11.3 Market Opportunity Analysis
  • 3.12 VRE - Vancomycin-resistant Enterococcus
    • 3.12.1 FDA Approved MDx Tests for VRE
    • 3.12.2 Market Opportunity Analysis
  • 3.13 VRE - Vancomycin-resistant Enterococcus
    • 3.13.1 FDA Approved MDx Tests for VRE
    • 3.13.2 Market Opportunity Analysis

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Chemical/Reagent Supplier
    • 4.1.5 Pathology Supplier
    • 4.1.6 Independent Clinical Laboratory
    • 4.1.7 Public National/regional Laboratory
    • 4.1.8 Hospital Laboratory
    • 4.1.9 Physicians Office Lab (POLS)
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
    • 4.2.3 Segmenting the Syndromic Testing Market
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
    • 4.3.3 Hospital vs. Central Lab
    • 4.3.4 Physician Office Lab's
    • 4.3.5 Physician's and POCT

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 New Genotypes Creating New Markets
    • 5.1.2 Aging Population a Boon for All Diagnostics
    • 5.1.3 Developing World Driving ID Dx Growth
    • 5.1.4 Point of Care - Why Centralization is Losing Steam
    • 5.1.5 Self Testing
    • 5.1.6 The Need for Speed
    • 5.1.7 The COVID Pandemic
  • 5.2 Factors Limiting Growth
    • 5.2.1 Lower Costs
    • 5.2.2 Infectious Disease is Declining
    • 5.2.3 Wellness Hurts
    • 5.2.4 Economic Growth improves Living Standards
  • 5.3 Instrumentation, Automation and Diagnostic Trends
    • 5.3.1 Traditional Automation and Centralization
    • 5.3.2 The New Automation, Decentralization and Point Of Care
    • 5.3.3 Instruments Key to Market Share
    • 5.3.4 Bioinformatics Plays a Role
    • 5.3.5 PCR Takes Command
    • 5.3.6 Next Generation Sequencing Fuels a Revolution
    • 5.3.7 NGS Impact on Pricing
    • 5.3.8 Whole Genome Sequencing, A Brave New World
    • 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment

6 Clinical Laboratory MDx Infectious Disease Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Spindiag Seeks Investors for Rapid PCR System
  • 6.3 Sorrento Therapeutics Nabs Contract for Dx Platform
  • 6.4 Kephera Planning Menu of Infectious Disease Tests
  • 6.5 Oxford Nanopore and BioMérieux to Develop IDDx
  • 6.6 SD Biosensor Eyes Global Expansion
  • 6.7 Selux Dx Next Gen Phenotyping Gets FDA Clearance
  • 6.8 Takara Developing High-Throughput Multiplex Panels
  • 6.9 BioGX Debuts New Point-of-Care Molecular Testing System
  • 6.10 Nanopath MDx Platform Providing 15-Minute Results
  • 6.11 ProtonDx Commercializing Rapid MDx Instrument
  • 6.12 Siemens Healthineers to Develop Next-Gen, High-Throughput MDx Platform
  • 6.13 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays
  • 6.14 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS
  • 6.15 Accelerate Diagnostics Anticipates Growth
  • 6.16 Growth of Decentralized Testing Expected to Continue
  • 6.17 Lumos Diagnostics Expanding Test Portfolio
  • 6.18 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens
  • 6.19 CareDx, IDbyDNA Develop Infectious Disease Dx for Transplant Patients
  • 6.20 Accelerated Development of CRISPR as a Diagnostic Platform
  • 6.21 Lab-on-a-Chip Infection Test Threatens Clinical Laboratory Role

7 Key Companies and Competitive Analysis

  • 7.1 Abbott Laboratories
  • 7.2 Beckman Coulter Diagnostics
  • 7.3 Becton, Dickinson and Company
  • 7.4 bioMérieux Diagnostics
  • 7.5 Bio-Rad Laboratories, Inc.
  • 7.6 Cepheid (Danaher)
  • 7.7 Hologic
  • 7.8 Ortho Clinical Diagnostics
  • 7.9 Perkin Elmer
  • 7.10 Qiagen
  • 7.11 Roche Molecular Diagnostics
  • 7.12 Siemens Healthineers
  • 7.13 Thermo Fisher Scientific Inc.

8 The Global Market for Clinical Laboratory MDx Infectious Disease

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Application - Overview
    • 8.2.1 Table - Global Market by Application
    • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Application - Base Year
    • 8.2.4 Chart - Global Market by Application - End Year
    • 8.2.5 Chart - Global Market by Application - Share by Year
    • 8.2.6 Chart - Global Market by Application - Segments Growth

9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Blood Borne Virus
    • 9.2.1 Table Blood Borne Virus - by Country
    • 9.2.2 Chart - Blood Borne Virus Growth
  • 9.3 Transplant
    • 9.3.1 Table Transplant - by Country
    • 9.3.2 Chart - Transplant Growth
  • 9.4 Hospital Acquired Infections
    • 9.4.1 Table Hospital Acquired Infections - by Country
    • 9.4.2 Chart - Hospital Acquired Infections Growth
  • 9.5 Reproductive Health
    • 9.5.1 Table Reproductive Health - by Country
    • 9.5.2 Chart - Reproductive Health Growth
  • 9.6 C19 Singleplex
    • 9.6.1 Table C19 Singleplex - by Country
    • 9.6.2 Chart - C19 Singleplex Growth
  • 9.7 Other
    • 9.7.1 Table Other - by Country
    • 9.7.2 Chart - Other Growth

10 Appendices

  • 10.1 United States Medicare System: Laboratory Fees Schedule
  • 10.2 The Most Used IVD Assays
  • 10.3 The Highest Grossing Assays